Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 3/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19223243 | 0.90 | NPC1 (0.41) | FTOMAPK1NPC1RAB9AWNT3A | |
| SCHEMBL16619783 | 0.89 | MAPK1 (0.37) | FTORORCMAPK1NPC1RAB9A | |
| SCHEMBL16620394 | 0.87 | MAPK1 (0.35) | NR2E1MAPK1WNT3APSEN1PSEN2 | |
| SCHEMBL16620566 | 0.86 | MAPK1 (0.35) | MAPK1WNT3APSEN1PSEN2APH1B | |
| SCHEMBL16630787 | 0.83 | KDM4C (0.40) | FTORORCMAPK1SORT1KDM4C | |
| SCHEMBL16620238 | 0.81 | MAPK1 (0.41) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16620241 | 0.81 | MAPK1 (0.41) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9959710 | 0.80 | KDM4E (0.38) | RORCMAPK1 | |
| SCHEMBL29511828 | 0.79 | MAPK1 (0.39) | MAPK1CYP3A4 | |
| SCHEMBL20474956 | 0.79 | MAPK1 (0.39) | MAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3363800-A1 | HETEROCYCLIC INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9951078-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3052096-B1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9624228-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3052096-A1 | INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015051341-A1 | INHIBITORS OF ERK AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301317-B2 | Inhibitors of ERK and methods of use | MAP3K1, MAP3K2, MAP3K6 | FTO 4882/4885RORC 1707/4885NR2E1 2219/4885 |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | FTO 4882/4885RORC 1707/4885NR2E1 2219/4885 |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | FTO 4882/4885RORC 1707/4885NR2E1 2219/4885 |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | FTO 4882/4885RORC 1707/4885NR2E1 2219/4885 |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | FTO 4882/4885RORC 1707/4885NR2E1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.